A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT06948435
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Hypertension
- Overweight or Obesity
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Orforglipron — DRUGAdministered orally
- Placebo — DRUGplacebo administered.
Study Details
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Key Dates
- Start date
- Apr 30, 2025
- Status verified
- May 2026
- Primary completion
- Sep 30, 2027
- Completion
- Sep 30, 2027
Study Design
- Enrollment
- 487 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: OrforglipronParticipants will receive orforglipron orally.
- Placebo Comparator: PlaceboAdministered placebo.
Primary Outcome Measure
Change from Baseline in office Systolic Blood Pressure (SBP) [ Time Frame: Baseline to Week 36 ]
Locations (28)
Find similar trials in Phoenix, AZ
By condition
By specialty
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effect of Electro-Acupuncture on Blood PressureRecruiting · University of California, Irvine · Irvine, California
- : Vascular Function in Health and DiseasePHASE1 · Recruiting · Russell Richardson · Salt Lake City, Utah
- Clinical and Molecular Characteristics of Primary Aldosteronism in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland